Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company whose news flow centers on the development of therapies for metabolic and endocrine disorders. Company press releases highlight progress across a pipeline that includes VK2735 for obesity and related metabolic conditions, VK2809 for lipid and liver disorders such as NASH and NAFLD, VK0214 for X-linked adrenoleukodystrophy (X-ALD), and an emerging program of dual amylin and calcitonin receptor agonists (DACRAs) for obesity and other metabolic diseases.
For VK2735, Viking regularly issues news on clinical milestones in both subcutaneous and oral tablet formulations. Recent announcements describe positive Phase 2 VENTURE trial results in obesity, with statistically significant weight loss and encouraging safety and tolerability, as well as Phase 2 VENTURE-Oral Dosing data showing meaningful weight reduction after 13 weeks of once-daily oral therapy. Additional releases cover the initiation and progress of the Phase 3 VANQUISH-1 and VANQUISH-2 trials, which evaluate weekly subcutaneous VK2735 in adults with obesity or overweight, including those with type 2 diabetes, over 78 weeks.
News items also detail exploratory maintenance dosing studies of VK2735 that examine monthly subcutaneous, weekly oral, and daily oral regimens following initial weight loss. Beyond obesity, Viking’s updates discuss VK2809’s Phase 2b success in biopsy-confirmed NASH and fibrosis, as well as Phase 2a results in NAFLD with elevated LDL-C, and VK0214’s Phase 1b data in X-ALD showing reductions in very long-chain fatty acids. Investors following VKTX news can expect coverage of clinical data presentations at scientific meetings, participation in healthcare and investor conferences, and SEC-reported corporate updates on financial results and pipeline status.
Viking Therapeutics (NASDAQ: VKTX) will release its financial results for Q4 and year-end 2021 on February 9, 2022, after market close. The company will also host a conference call at 4:30 PM ET to discuss these results, along with general corporate updates. Investors can participate via phone or listen to the live webcast on Viking's website. Viking is focused on developing therapies for metabolic disorders, with candidates like VK2809, VK0214, and VK2735 in various stages of clinical trials.
Viking Therapeutics, Inc. (VKTX) announced a clinical hold by the FDA on its Phase 1b trial of VK0214 for X-linked adrenoleukodystrophy (X-ALD). The FDA requires an additional preclinical study, specifically a rodent genotoxicity study, before the trial can continue. This hold is not based on any findings from prior studies. The company expects to submit the requested data in Q2 2022, aiming to resume dosing later this year. VK0214 has previously shown promising safety and efficacy results, including reductions in LDL cholesterol and triglycerides.
Viking Therapeutics (NASDAQ: VKTX) announced the initiation of a Phase 1 clinical trial for VK2735, a novel dual agonist targeting GLP-1 and GIP receptors, aimed at treating metabolic disorders. This double-blind, placebo-controlled study will assess safety, tolerability, and pharmacokinetics in healthy adults, with exploratory assessments of body weight and liver fat changes. VK2735 is expected to enhance therapeutic effects compared to existing treatments like semaglutide. The trial marks a significant milestone for Viking, which aims to report topline results later in the year.
Viking Therapeutics (NASDAQ: VKTX) announced that CEO Brian Lian, Ph.D., will present at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be available online once the conference begins, with a webcast accessible via Viking's website. Viking Therapeutics focuses on developing innovative therapies for metabolic and endocrine disorders, including its lead candidates VK2809 and VK0214, which are in advanced stages of clinical trials.
Viking Therapeutics (NASDAQ: VKTX) will present at the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021. CEO Brian Lian, Ph.D., is scheduled to speak on November 16 from 4:00 to 4:30 p.m. Eastern. Interested parties can access the presentation via the company's website, with a replay available post-conference. Viking focuses on therapies for metabolic and endocrine disorders, including VK2809, currently in a Phase 2b study for non-alcoholic steatohepatitis.
Viking Therapeutics (VKTX) reported its Q3 2021 financial results with a net loss of $13.2 million ($0.17 per share), compared to a loss of $9.3 million ($0.13 per share) in Q3 2020. The increase in loss was attributed to rising research and development expenses, now totaling $10.8 million, primarily for clinical studies. Viking is advancing its clinical pipeline, including ongoing Phase 2b VOYAGE trial for VK2809 in NASH and Phase 1b trial for VK0214 in X-ALD. The company ended Q3 with $216 million in cash, positioning it well for future developments.
Viking Therapeutics (NASDAQ: VKTX) presented preclinical data on dual GLP-1/GIP agonists at ObesityWeek 2021. The findings demonstrate significant weight loss and metabolic improvements in diet-induced obese mice, with weight reductions of up to 28%, and enhanced glucose and insulin responses compared to vehicle and semaglutide. The study results support the efficacy of dual agonists and provide a foundation for a forthcoming Phase 1 trial of a lead candidate. CEO Brian Lian emphasized the potential of these compounds in advancing treatment for metabolic disorders.
Viking Therapeutics (VKTX), a clinical-stage biopharmaceutical firm, will announce its third-quarter 2021 financial results on November 3, 2021, after market close. A conference call to discuss these results will follow at 4:30 p.m. ET. The company is developing oral therapies for metabolic and endocrine disorders, including VK2809, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH). VK2809 has shown efficacy in reducing LDL-C and liver fat in prior studies. The firm holds exclusive rights to five therapeutic programs from Ligand Pharmaceuticals.
Viking Therapeutics (NASDAQ: VKTX) announced the presentation of promising preclinical data on novel dual agonists targeting GLP-1 and GIP receptors at ObesityWeek 2021, occurring from November 1-5, 2021. Results from studies in diet-induced obese mice highlight significant weight loss and improved metabolic profiles. The poster presentations will be led by Kader Yagiz, Ph.D. This research could enhance Viking's pipeline of therapies for metabolic and endocrine disorders, further supporting its clinical programs, including VK2809 for NASH and fibrosis.
Viking Therapeutics (NASDAQ: VKTX) will have CEO Brian Lian, Ph.D., present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021. The virtual presentation is scheduled for 11:00 – 11:20 a.m. Eastern. Viking is focused on developing innovative therapies for metabolic and endocrine disorders, including VK2809, a selective thyroid hormone receptor beta agonist currently in Phase 2b for NASH. The company is also developing VK0214 for X-linked adrenoleukodystrophy (X-ALD).